Shougang LanzaTech Defines Comprehensive Remuneration and Appraisal Committee Mandate

Bulletin Express
06/02

Beijing Shougang LanzaTech Technology Co., Ltd. (Shougang LanzaTech) has published detailed Terms of Reference setting out the authority, composition and operating procedures of its Board Remuneration and Appraisal Committee.

The committee will comprise a minimum of three directors, with independent non-executive directors forming the majority. An independent non-executive director will serve as chairman. A quorum requires two members, and the committee must convene at least once per year, providing seven-day notice for regular meetings.

Key duties include: • Formulating and recommending the overall remuneration policy and structure for directors and senior management. • Reviewing management’s remuneration proposals against Board-approved corporate goals. • Recommending individual compensation packages—covering salary, bonuses, benefits, pension rights and termination payments—for executive directors, non-executive directors and senior management. • Approving incentive and share schemes in line with Hong Kong Listing Rules (including Chapter 17). • Ensuring no director or associate participates in decisions on his or her own remuneration. • Assessing performance, overseeing service contracts and vetting termination and misconduct-related compensation to confirm fairness and contractual compliance.

The committee is empowered to access management, commission external professional advice at the company’s expense and must report its decisions and recommendations to the Board, subject to regulatory constraints. It will also review its own effectiveness and the adequacy of its mandate periodically.

The committee’s chairman, or a designated representative, will attend the company’s annual general meeting to answer shareholder questions about remuneration governance. The Terms of Reference take effect upon Board approval, while provisions specific to listed companies become operative upon Shougang LanzaTech’s share listing. Future regulatory changes will override any conflicting clauses, with prompt amendments to be submitted to the Board for approval.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10